

PEDONCOVID - SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Head :ROUGER-GAUDICHON Jérémie

Last update : 05/05/2021 | Version : 1 | ID : 73865

General

Identification

Detailed name SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology

Sign or acronym PEDONCOVID

General Aspects

Medical area Pediatrics

Study in connection with Covid-19 Yes

Pathology (details) Paediatric oncology

Keywords cancer; paediatrics; chemotherapy; SARS-CoV-2; COVID-19

Scientific investigator(s) (Contact)

Name of the director ROUGER-GAUDICHON

Surname Jérémie

Organization CHU Caen Normandie

Collaborations

Funding

Governance of the database

Sponsor(s) or organisation(s) responsible CHU Caen Normandie

Organisation status Public

Additional contact

Main features

Type of database

Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No

Database objective

Main objective	Describe the presentation and clinical course of SARS-CoV-2 infection among patients followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre, for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy.
----------------	---

Inclusion criteria	<p>Children and legal representatives, or adult patients having received information on the study AND</p> <ul style="list-style-type: none">- Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy <p>AND</p> <ul style="list-style-type: none">- Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology <p>OR</p> <ul style="list-style-type: none">- Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with:<ul style="list-style-type: none">o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash. <p>AND</p>
--------------------	---

o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a “crazy-paving” appearance, linear condensations with or without peripheral halo (reverse halo sign).

Population type

Age
Newborns (birth to 28 days)
Infant (28 days to 2 years)
Early childhood (2 to 5 years)
Childhood (6 to 13 years)
Adolescence (13 to 18 years)

Population covered Sick population

Pathology II - Neoplasms

Gender
Male
Woman

Geography area National

Data collection

Dates

Size of the database

Size of the database (number of individuals) < 500 individuals

Data

Database activity Current data collection

Type of data collected
Clinical data
Biological data

Clinical data (detail) Direct physical measures

Presence of a biobank No

Procedures

Followed pathology

Promotion and access

Promotion

